Orcinol glucoside

Name: Orcinol glucoside
Brand: MedChemExpress
SKU: HY-N0008
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0008 Purity: 99.40%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases.

For research use only. We do not sell to patients.

Orcinol glucoside Chemical Structure

CAS No. : 21082-33-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Orcinol glucoside:

Orcinol glucoside (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Wnt Isoform Specific Products:

View All Isoforms

Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms

ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Orcinol glucoside (1-10 μM; 72 h) does not reduce the viability of H₂O₂-exposed RAW264.7 cells^[1].
Orcinol glucoside (1-10 μM; 72 h) dose-dependently inhibits the differentiation and TRAP activity of RANKL- and H₂O₂-induced RAW264.7 osteoclasts^[1].
Orcinol glucoside (5-10 μM; 48 h pre-incubation with RANKL before 4 h H₂O₂ exposure) activates the mTOR pathway in RANKL- and H₂O₂-induced RAW264.7 osteoclasts, increasing phosphorylation of mTOR and p70S6K^[1].
Orcinol glucoside (10-100 nM; 72 h) promotes proliferation of primary mouse osteoblast cells in a dose-dependent manner at concentrations of 10, 50, and 100 nM over 72 h^[2].
Orcinol glucoside (10-100 nM) upregulates p38 phosphorylation and the expression of osteogenic-related proteins (Collagen I, Runx2, Osx, Dlx5) in primary mouse osteoblast cells in vitro in a dose-dependent manner at concentrations of 10, 50, and 100 nM^[2].
Orcinol glucoside (0-100 µM; 48 h) is non-toxic to NIH/3T3 mouse fibroblasts and HFL-1 human fibroblasts at concentrations ranging from 0 to 100 µM after 48 h incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	murine macrophage RAW264.7 cells
Concentration:	1-10 μM
Incubation Time:	72 h
Result:	Exerted no cytotoxic effects on RAW264.7 cells, with cell viability remaining comparable to control groups.

Cell Differentiation Assay^[1]

Cell Line:	RANKL- and H₂O₂-induced RAW264.7 cells
Concentration:	1-10 μM
Incubation Time:	72 h
Result:	Decreased the number of TRAP-positive multinucleated osteoclasts and reduced TRAP activity in a dose-dependent manner compared to the H₂O₂-only treated group.

In Vivo

Orcinol glucoside (50-100 mg/kg, intragastric administration; daily dosing; for 10 consecutive weeks) alleviates senile osteoporosis in SAMP6 mice, significantly improves bone microstructure, reduces the levels of bone resorption biomarkers, and regulates oxidative stress and autophagy via the Nrf2/Keap1 and mTOR signaling pathways^[1].
Orcinol glucoside (5-20 mg/kg, intragastric administration; daily dosing; for 8 consecutive weeks) dose-dependently increases BMD, BV/TV, Tb.Th and Tb.N in dexamethasone-induced osteoporotic mice by activating the p38 signaling pathway and upregulating downstream osteogenic proteins^[2].
Orcinol glucoside (5 mg/kg, intragastric administration, once daily for 5 consecutive weeks) improves the bone microstructure and increases osteogenic biomarkers in dexamethasone-induced osteoporotic mice by activating p38, while p38 inhibitors block these effects^[2].
Orcinol glucoside (25-100 mg/kg; p.o.; once daily; for 14 consecutive days) dose-dependently alleviates bleomycin-induced pulmonary fibrosis in male C57BL/6J mice by inhibiting the expression of fibrosis markers, HA accumulation, and TGF-β₁ production, with an exposure-response relationship observed across different administration doses^[3].
Orcinol glucoside (5-20 mg/kg; p.o.; single administration) exhibits anxiolytic activity in mice without inducing sedative effects^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (male, 8 weeks old, dexamethasone-induced osteoporosis)^[2]
Dosage:	5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:	i.g.; daily; 8 weeks
Result:	Increased bone mineral density (BMD), trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N) in a dose-dependent manner compared to the dexamethasone-only group. Reversed dexamethasone-induced reductions in serum osteoblast-associated markers type I procollagen amino-terminal extension peptide (PINP) and alkaline phosphatase (ALP). Increased femoral tissue expression of p38, phosphorylated p38 (p-p38), Collagen I, Runx2, Osx, Dlx5, glucocorticoid receptor (GR), and phosphorylated GR Ser226 (p-GR226).

Animal Model:	CD-1 (male, 18-22 g)^[4]
Dosage:	5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:	p.o.; single dose
Result:	Significantly increased the time spent in open arms and number of entries into open arms in the elevated plus-maze test compared to vehicle control. Significantly increased the number of head-dips in the hole-board test compared to vehicle control (at 5 and 10 mg/kg). Did not cause significant changes in mouse locomotor counts in the open-field test compared to vehicle control.

Molecular Weight

286.28

Formula

C₁₃H₁₈O₇

CAS No.

21082-33-7

Appearance

Solid

Color

White to off-white

SMILES

CC1=CC(O)=CC(O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (436.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4931 mL	17.4654 mL	34.9308 mL
5 mM	0.6986 mL	3.4931 mL	6.9862 mL
10 mM	0.3493 mL	1.7465 mL	3.4931 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.40%

Select Batch:

Data Sheet (282 KB) SDS (393 KB)

COA (250 KB) LCMS (87 KB)

Handling Instructions (2659 KB)

References

[1]. Gong W, et al. Orcinol Glucoside Improves Senile Osteoporosis through Attenuating Oxidative Stress and Autophagy of Osteoclast via Activating Nrf2/Keap1 and mTOR Signaling Pathway. Oxid Med Cell Longev. 2022;2022:5410377. Published 2022 May 9.

[2]. He XY, et al. Orcinol glucoside targeted p38 as an agonist to promote osteogenesis and protect glucocorticoid-induced osteoporosis. Phytomedicine. 2023;119:154953.

[3]. Li C, et al. Orcinol glucoside ameliorates pulmonary fibrosis by suppressing hyaluronic acid synthesis and macrophage M2 polarization via targeting hyaluronic acid synthase 2. Int J Mol Med. 2026;57(4):93.

[4]. Wang X, et al. Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice. Pharm Biol. 2015;53(6):876-881. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4931 mL	17.4654 mL	34.9308 mL	87.3271 mL
	5 mM	0.6986 mL	3.4931 mL	6.9862 mL	17.4654 mL
	10 mM	0.3493 mL	1.7465 mL	3.4931 mL	8.7327 mL
	15 mM	0.2329 mL	1.1644 mL	2.3287 mL	5.8218 mL
	20 mM	0.1747 mL	0.8733 mL	1.7465 mL	4.3664 mL
	25 mM	0.1397 mL	0.6986 mL	1.3972 mL	3.4931 mL
	30 mM	0.1164 mL	0.5822 mL	1.1644 mL	2.9109 mL
	40 mM	0.0873 mL	0.4366 mL	0.8733 mL	2.1832 mL
	50 mM	0.0699 mL	0.3493 mL	0.6986 mL	1.7465 mL
	60 mM	0.0582 mL	0.2911 mL	0.5822 mL	1.4555 mL
	80 mM	0.0437 mL	0.2183 mL	0.4366 mL	1.0916 mL
	100 mM	0.0349 mL	0.1747 mL	0.3493 mL	0.8733 mL